Royal Philips plans to team up with Ypsomed to install digital, self-medication adherence tracking across a line of connected liquid drug delivery devices, including injection and infusion systems used in diabetes, multiple sclerosis and rheumatoid arthritis.
The two companies signed a memorandum of understanding to build out Ypsomed’s new SmartServices platform, based on Philips’ cloud-based HealthSuite, to offer value-added products to the industry and extend Ypsomed’s medical device business.
The Switzerland-based Ypsomed Group supplies pens, autoinjectors and infusion hardware to pharmaceutical companies, as well as directly to patients for at-home use. The companies aim to sign a definitive agreement before the end of the year.
“Our partnership with Philips aims at embedding smart devices in a digital health ecosystem that simplifies access to therapy-relevant medication adherence data,” said Ulrike Bauer, senior VP at Ypsomed Delivery Systems.
RELATED: Philips inks 11-year deal for patient monitoring as a service
“This will allow our pharmaceutical customers to focus on building therapy-specific digital solutions for patients, caregivers and physicians,” Bauer said.
“It will shorten time-to-market, enable them to scale-up solutions in a secure HIPAA-compliant way, and allow them to integrate data from Ypsomed devices with other data sources to support many different value-added use cases,” added Dale Wiggins, business leader for the HealthSuite platform at Philips.
Ypsomed’s portfolio includes the consumer-focused mylife Diabetescare brand, as well as YDS Ypsomed Delivery Systems for business-to-business sales.